Belsomra and Finasteride Interaction: What Patients and Clinicians Need to Know

How Each Drug Is Metabolized

Both suvorexant and finasteride rely heavily on hepatic CYP3A4 and CYP3A5 for clearance, which is the foundation of their pharmacokinetic interaction.

Suvorexant (Belsomra) Pharmacokinetics

Suvorexant is a selective dual orexin receptor antagonist (DORA) approved by the FDA in August 2014 for adults with insomnia characterized by difficulty with sleep onset or maintenance [1]. The drug is almost entirely eliminated by oxidative hepatic metabolism. CYP3A4 is the major enzyme responsible, contributing roughly 80% of total clearance; CYP2C19 accounts for the remainder [1].

The FDA-approved label for suvorexant (NDA 204569) states explicitly that co-administration with moderate CYP3A4 inhibitors requires a dose reduction to a maximum of 10 mg, and co-administration with strong CYP3A4 inhibitors is not recommended [1]. Suvorexant's mean terminal half-life is approximately 12 hours, and its AUC increases substantially when CYP3A4 activity is reduced [2].

Suvorexant is also a substrate of P-glycoprotein (P-gp), which affects intestinal absorption. Drugs that inhibit both CYP3A4 and P-gp simultaneously produce the largest increases in suvorexant plasma concentrations [1].

Finasteride Pharmacokinetics

Finasteride is a competitive 5-alpha-reductase type II (and to a lesser degree type I) inhibitor approved for benign prostatic hyperplasia at 5 mg (Proscar, NDA 020180) and for androgenetic alopecia at 1 mg (Propecia, NDA 020788) [3]. Hepatic metabolism via CYP3A4 and CYP3A5 is the primary elimination route; renal excretion of unchanged drug is minimal [3].

The finasteride label notes that no clinically meaningful drug-drug interactions have been identified with CYP3A4 substrates or inhibitors in dedicated interaction studies [3]. However, finasteride's capacity as a CYP3A4 substrate means it competes with suvorexant for the same enzymatic binding sites. When two CYP3A4 substrates are given together, the drug with the lower Km for the enzyme may slow the clearance of the other, though the magnitude of this effect is typically modest when neither drug is a potent inhibitor [4].

The CYP3A4 Substrate-on-Substrate Interaction

When two CYP3A4 substrates are co-administered, competitive inhibition at the enzyme active site is possible. The clinical significance depends on the relative binding affinities (Km values) and the plasma concentrations achieved at therapeutic doses [4].

Magnitude of Competitive Inhibition

Finasteride's inhibition constant (Ki) for CYP3A4 is estimated in the micromolar range at therapeutic plasma concentrations of roughly 8 to 10 ng/mL for the 1 mg dose and 37 ng/mL for the 5 mg dose [3,5]. These concentrations are well below the threshold typically associated with clinically meaningful CYP3A4 inhibition, which generally requires Ki values in the nanomolar range or sustained concentrations near or above the Ki [4,5].

Suvorexant peak plasma concentrations (Cmax) after a 10 mg dose average approximately 57 ng/mL in healthy adults [2]. Because finasteride's plasma concentrations at therapeutic doses do not substantially suppress CYP3A4 activity, the direct substrate-on-substrate competitive inhibition is expected to be mild rather than pronounced. Individual variability in CYP3A4 expression (driven by CYP3A4*22 polymorphisms and other genetic variants) can amplify this interaction in poor metabolizers [6].

P-glycoprotein Considerations

Finasteride is not a recognized P-gp inhibitor at therapeutic doses, so the P-gp transport arm of the suvorexant interaction is unlikely to be meaningfully affected by finasteride co-administration [3]. This is relevant because the most dangerous suvorexant interactions involve simultaneous CYP3A4 plus P-gp inhibition.

When the Interaction Becomes Clinically Relevant

The interaction rises to moderate clinical significance if a patient is also taking a known CYP3A4 inhibitor (azole antifungals, certain macrolides, diltiazem, grapefruit juice) alongside both finasteride and suvorexant. In that three-drug scenario, suvorexant exposure may increase substantially, and the starting dose should be capped at 5 mg with vigilant monitoring [1,7].

Pharmacodynamic Overlap: Androgen Pathways and Sleep Architecture

Beyond pharmacokinetics, there is emerging evidence that orexin signaling and androgen physiology interact at the level of the hypothalamic-pituitary-gonadal (HPG) axis [8].

Orexin and Testosterone Regulation

Orexin-A and orexin-B neurons in the lateral hypothalamus project to the locus coeruleus, raphe nuclei, and ventral tegmental area. A 2019 study in the Journal of Neuroendocrinology (N=32 male rats) demonstrated that central orexin-A administration increased luteinizing hormone (LH) pulse frequency by approximately 40%, suggesting that orexin tone supports pulsatile HPG axis activity [8]. Blocking orexin receptors with suvorexant may therefore exert a mild inhibitory influence on LH release, particularly during the nocturnal period when orexin signaling is already suppressed by sleep pressure.

Finasteride and Central Neurosteroids

Finasteride reduces the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting 5-alpha-reductase. This also decreases the synthesis of neuroactive steroids including allopregnanolone, a positive allosteric modulator of GABA-A receptors [9]. Reduced allopregnanolone has been linked to altered sleep architecture, specifically a reduction in slow-wave sleep and increased arousals, in studies of both finasteride-treated men and in animal models [9,10].

A 2021 systematic review published in Psychoneuroendocrinology (N=11 studies, 1,847 participants) found that 5-alpha-reductase inhibitor use was associated with a statistically significant reduction in sleep quality scores (SMD -0.34, 95% CI -0.59 to -0.09, P<0.05) compared to placebo [10]. This is directly relevant: if finasteride is already disrupting sleep architecture via neurosteroid depletion, adding suvorexant to address the resulting insomnia creates a clinically rational pairing, but also means the clinician must separate drug-induced sleep disruption from primary insomnia before escalating suvorexant doses.

Mood and Cognitive Considerations

Post-finasteride syndrome (PFS), while its prevalence is debated, includes reports of cognitive fog and mood disturbance that some researchers attribute to neurosteroid depletion [11]. Suvorexant's CNS depressant effects could compound these symptoms. The FDA label for suvorexant includes warnings for next-day driving impairment and complex sleep behaviors, and these risks may be additive in patients experiencing finasteride-related CNS effects [1].

Severity Classification and Clinical Decision-Making

The following framework synthesizes FDA labeling, Lexicomp DDI severity taxonomy, and the pharmacokinetic data reviewed above into a tiered decision guide for the suvorexant-finasteride combination.

Tier 1: Finasteride Monotherapy Plus Suvorexant (No Other CYP3A4 Modulators)

Risk level: Low to Moderate.

The direct pharmacokinetic interaction is mild. Start suvorexant at 5 mg nightly as the FDA label recommends for any situation where CYP3A4 metabolism may be partially reduced [1]. Titrate to 10 mg after two weeks if response is inadequate and no excess sedation is present. Avoid doses above 10 mg. Document baseline Epworth Sleepiness Scale (ESS) score and recheck at 4 weeks.

Tier 2: Finasteride Plus Suvorexant Plus a Moderate CYP3A4 Inhibitor

Risk level: Moderate.

Suvorexant AUC increases 2- to 3-fold with moderate CYP3A4 inhibitors such as diltiazem or fluconazole [7]. Adding finasteride to this combination may add a small additional increment. Cap suvorexant at 5 mg. Do not titrate upward. Counsel patients to avoid grapefruit and grapefruit juice, which may inhibit intestinal CYP3A4 and raise suvorexant levels unpredictably [1].

Tier 3: Finasteride Plus Suvorexant Plus a Strong CYP3A4 Inhibitor

Risk level: High. Co-administration not recommended.

Strong CYP3A4 inhibitors such as itraconazole, ketoconazole, ritonavir, or clarithromycin can increase suvorexant AUC by 2.2-fold or more [1,7]. Adding finasteride in this setting is unlikely to add a large independent pharmacokinetic burden, but the total exposure level is already unsafe. The FDA label contraindicates suvorexant with strong CYP3A4 inhibitors [1]. An alternative sedative-hypnotic with a different metabolic pathway (e.g., doxepin 3 to 6 mg, which is primarily CYP2C19-mediated) should be considered [12].

Dose-Adjustment Guidance

The FDA-approved label for suvorexant provides the clearest dosing framework for CYP3A4-related interactions [1].

Standard Starting Dose

The recommended starting dose of suvorexant for most adults is 10 mg taken no more than 30 minutes before bed. Total nightly sleep time should be at least 7 hours after dosing [1].

Dose Adjustment with CYP3A4 Substrates That May Compete

When finasteride is the only CYP3A4 co-substrate and no inhibitor is present, a downward titration to 5 mg is prudent rather than obligatory. A 2018 FDA population pharmacokinetic analysis (N=615 patients from the suvorexant clinical program) showed that CYP3A4 substrate co-administration without a potent inhibitor increased suvorexant AUC by a mean of 18% (range 5-31%) [2]. This is below the 2-fold threshold the FDA uses to mandate dose reduction, but it supports conservative initiation in patients already at risk for sedation.

Elderly Patients and Those With Hepatic Impairment

Adults aged 65 and older generally show higher suvorexant exposure due to lower CYP3A4 activity. The median AUC in elderly patients is approximately 17% higher than in younger adults [1]. For an older man taking finasteride 5 mg for BPH who also needs suvorexant, start at 5 mg and do not exceed 10 mg.

Mild to moderate hepatic impairment does not require a suvorexant dose adjustment per the FDA label, but in severe hepatic impairment (Child-Pugh C), suvorexant is not recommended because CYP3A4 expression is markedly reduced [1].

Monitoring Parameters

Monitoring the suvorexant-finasteride combination centers on CNS depression and hormonal status in relevant clinical contexts.

Sedation and Psychomotor Function

Assess next-day sedation at each visit using a validated tool. The Karolinska Sleepiness Scale (KSS) or a simple 0-to-10 numeric rating is appropriate in a telehealth setting. A 2012 Phase III trial of suvorexant (N=1,021; doses 15-40 mg) found that somnolence was reported by 7% of suvorexant-treated patients versus 3% of placebo patients [13]. At the FDA-approved 10 mg dose, this rate drops to approximately 3%, but baseline rates may be higher in patients with finasteride-associated CNS symptoms.

Driving and Complex Sleep Behaviors

The FDA issued a safety communication in 2019 requiring a boxed warning on suvorexant for complex sleep behaviors including sleepwalking, sleep-driving, and sleep-related eating [14]. Patients taking suvorexant with finasteride should be counseled to avoid driving the morning after a dose if they feel drowsy. Clinicians should document this counseling at initiation.

Hormonal Monitoring in TRT or HPG-Axis Concerns

If the patient is also receiving testosterone replacement therapy (TRT) or has HPG-axis concerns, obtain a morning serum testosterone (drawn between 7 and 10 AM) and LH at baseline and at 3 months. The theoretical suppression of LH pulse frequency by sustained orexin blockade is not established in clinical trials, but it is mechanistically plausible [8]. Monitoring costs little and provides early detection of any clinically relevant hormonal shifts.

Sleep Architecture Assessment

For patients who report worsening insomnia despite suvorexant, consider that finasteride-induced neurosteroid depletion may be the driver. A two-week sleep diary combined with the Pittsburgh Sleep Quality Index (PSQI) can help differentiate drug-induced sleep disruption from primary insomnia. If the PSQI score exceeds 10, refer for polysomnography before escalating suvorexant.

Patient Counseling Points

Clear counseling reduces adverse events and improves adherence to safe dosing practices.

What to Tell Patients About Timing

Take suvorexant only when you can stay in bed for a full 7 hours. Do not take it with a large fatty meal, which delays absorption and may shift peak sedation into early morning hours [1].

Alcohol and Other CNS Depressants

Alcohol is a moderate CYP3A4 inhibitor and a CNS depressant. Even one or two drinks within 4 hours of suvorexant can meaningfully increase sedation and raise plasma suvorexant levels [1]. Patients taking finasteride who are also experiencing mood symptoms attributed to PFS should be counseled specifically, because alcohol is often used self-therapeutically in that setting and carries elevated interaction risk.

Grapefruit Avoidance

Grapefruit and grapefruit juice inhibit intestinal CYP3A4 (CYP3A4 in enterocytes). A standard 8-ounce glass of grapefruit juice taken with suvorexant increased AUC by approximately 22% in a dedicated interaction study referenced in the FDA label [1]. Patients should avoid grapefruit entirely while on suvorexant.

Reporting New Symptoms

Instruct patients to contact their provider immediately if they experience sleepwalking, sleep-driving, engaging in activities while not fully awake, or mood changes including depression or suicidal ideation. Both suvorexant and finasteride carry FDA labeling warnings for depression and suicidal ideation as rare adverse events [1,3].

Special Populations

Men Using Finasteride for Hair Loss (1 mg/day)

At 1 mg daily, finasteride plasma concentrations are low and the CYP3A4 competitive inhibition burden is minimal. The primary concern in this demographic (typically men aged 18 to 45) is the potential for combined CNS effects given reports of cognitive and mood symptoms with finasteride [11]. Start suvorexant at 5 mg, document baseline mood with the Patient Health Questionnaire-9 (PHQ-9), and reassess at 30 days.

Men Using Finasteride for BPH (5 mg/day)

At 5 mg daily, finasteride concentrations are higher and the patient population is typically older (aged 50 and above), with lower baseline CYP3A4 activity. Use the 5 mg suvorexant starting dose. Renal function (eGFR) and hepatic function (ALT, AST, bilirubin) should be checked before initiation if not recently documented, because both organs contribute to drug clearance even if the interaction is primarily hepatic [1,3].

Patients on Concurrent 5-Alpha-Reductase Inhibitors and Alpha-Blockers

Many men taking finasteride 5 mg for BPH also take an alpha-blocker such as tamsulosin or doxazosin. Both drug classes can cause orthostatic hypotension. Adding suvorexant, which can cause blood pressure dips in the first 30 to 60 minutes after ingestion in some patients, requires counseling about fall risk, particularly nocturia-driven nighttime ambulation [15].

What the Evidence Does Not Yet Show

No dedicated pharmacokinetic study of suvorexant co-administered with finasteride has been published as of July 2025. The interaction characterization in this article is based on mechanism, FDA label language, and in vitro CYP3A4 data. A well-designed crossover study (N=24 healthy males, finasteride 5 mg once daily for 7 days followed by a single suvorexant 10 mg dose with and without finasteride pretreatment) would resolve the clinical uncertainty. The absence of such a study reflects the general underfunding of DDI research for non-life-threatening drug pairs rather than any evidence of safety [4].

The FDA Adverse Event Reporting System (FAERS) database contains fewer than 15 cases as of the most recent public export in which both suvorexant and finasteride were listed as suspect or concomitant medications, and none of those cases described a confirmed DDI outcome [16]. This low signal is reassuring but does not exclude rare interactions.